SEC Filing Summary: Form 13F Information Table
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Alphabet Inc. to the U.S. Securities and Exchange Commission. The reporting period covers holdings as of March 31, 2022. This document discloses the equity securities held by Alphabet Inc. that are subject to reporting requirements under Section 13(f) of the Exchange Act. It does not contain Alphabet's own financial performance data (revenue, profit, etc.) but rather details its investment portfolio in other public companies.
Key Financial Metrics and Portfolio Composition
The filing lists specific equity positions held by Alphabet Inc. Key metrics include the title of the class, CUSIP, value (in thousands), and number of shares. The portfolio is heavily concentrated in the technology, biotechnology, and healthcare sectors.
Top Holdings by Value (Selected Examples):
- IonQ Inc: 21,907,038 shares valued at $279,534,000.
- Planet Labs PBC: 31,942,641 shares valued at $162,269,000.
- Oscar Health Inc: Multiple tranches totaling over 23 million shares with a combined value exceeding $25 million (specific tranches range from $255k to $21.3M).
- UiPath Inc: Two tranches totaling 14,068,674 shares valued at approximately $14.5 million.
- Verve Therapeutics Inc: 10,974,011 shares valued at $246,306,000.
- 23andMe Holding Co: 6,736,785 shares valued at $25,802,000.
Voting Authority: For all listed securities, Alphabet Inc. reports Sole voting authority (Column 7) and None for shared or none (Column 8). The investment discretion is marked as "DFND" (Discretionary) for all entries.
Material Changes and Comparisons
The provided text contains only the snapshot of holdings as of March 31, 2022. It does not include the prior quarter's data (December 31, 2021) within this specific text block. Therefore, material changes versus the prior comparable period cannot be calculated from this source alone. The filing lists current positions but lacks the historical delta required to identify new purchases or sales.
Guidance, Outlook, and Risks
Management Commentary: This filing is a regulatory disclosure of holdings and contains no management commentary, forward-looking guidance, or strategic outlook regarding Alphabet Inc.'s operations or investment thesis.
Risks and Contingencies: The filing includes a standard SEC disclaimer stating that the Commission has not reviewed the information for accuracy or completeness. No specific contingencies or risk factors related to the underlying investments are detailed in this table.
Unusual Items: The portfolio includes a significant number of positions in pre-revenue or early-stage biotechnology and life sciences companies (e.g., Alector, Arcus Biosciences, Beam Therapeutics), which typically carry higher volatility and risk profiles compared to mature technology firms.
Investor Verification Checklist
- Portfolio Concentration: Verify the total aggregate value of these holdings against Alphabet's total assets to determine the significance of this investment portfolio.
- Valuation Volatility: Confirm the current market prices of the listed biotech and tech stocks (e.g., IonQ, Planet Labs, Oscar Health) as these sectors experienced significant volatility in 2022.
- Transaction History: Cross-reference this filing with the Q4 2021 13F filing to identify specific buy/sell activity for the quarter.
- Voting Rights: Note that Alphabet holds sole voting authority for all listed positions, indicating direct control over proxy voting for these specific shares.
- Regulatory Status: Acknowledge that this is a self-reported form; the SEC does not verify the accuracy of the share counts or values listed.